H.C. Wainwright lowered the firm’s price target on Innate Pharma (IPHA) to $11 from $11.50 and keeps a Buy rating on the shares. The firm postponed the U.S. launch of IPH6101 to 2029 from previously estimated 2027 and EU launch to 2030 from 2028.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA: